AI assistant
BIO-TECHNE Corp — Director's Dealing 2022
Feb 3, 2022
30718_dirs_2022-02-03_1bf5d810-be05-4d6e-aa74-c27846dee05e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-02-01
Reporting Person: Geist William (President, Protein Sciences)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-01 | Common Stock | A | 2490 | — | Acquired | 2490 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-01 | Restricted Stock Units | $ | A | 840 | Acquired | Common Stock (840) | Direct | |
| 2022-02-01 | Stock Option (right to buy) | $401.57 | A | 2984 | Acquired | 2029-02-01 | Common Stock (2984) | Direct |
| 2022-02-01 | Stock Option (right to buy) | $401.57 | A | 3978 | Acquired | 2029-02-01 | Common Stock (3978) | Direct |
Footnotes
F1: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F3: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F4: Options to purchase 995 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 994 shares vest on each of 2/1/2025 and 2/1/2026.